HTA82 Surrogate Measures and the Health Technology Assessment of Cancer Drugs in Ireland: A Retrospective Analysis of EMA Cancer Drug Indication Approvals Between 2017 and 2022 and Recommendations Made By the NCPE in Ireland
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.1766
https://www.valueinhealthjournal.com/article/S1098-3015(23)04896-9/fulltext
Title :
HTA82 Surrogate Measures and the Health Technology Assessment of Cancer Drugs in Ireland: A Retrospective Analysis of EMA Cancer Drug Indication Approvals Between 2017 and 2022 and Recommendations Made By the NCPE in Ireland
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04896-9&doi=10.1016/j.jval.2023.09.1766
First page :
Section Title :
Open access? :
No
Section Order :
11207